Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hidradenitis Clear all
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06603077
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
36
States / cities
Scottsdale, Arizona • Tucson, Arizona • Northridge, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03827798
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa

NCT06361836
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
SBT777101
Biological
Lead sponsor
Sonoma Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Anifrolumab for Hidradenitis Suppurativa

NCT06374212
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
Interventions
Anifrolumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.

NCT02781818
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Triamcinolone Acetonide 10mg/mL, Triamcinolone Acetonide 40mg/mL, Normal Saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Sep 25, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional

Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06118099
View directory record Official record
Conditions
Hidradenitis
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Phoenix, Arizona • Fremont, California • Margate, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Not yet recruiting No phase listed Observational

A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa

NCT06201858
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2024 · Synced Sep 25, 2026, 5:09 AM EDT
Not listed Phase 2 Interventional

Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa

NCT05020730
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
PTM-001, Placebo
Drug
Lead sponsor
Phoenicis Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Redwood City, California • Worcester, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 25, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

NCT05997277
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa

NCT05322473
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Sonelokimab (M1095), Adalimumab, Placebo
Drug · Other
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Fountain Valley, California • Los Angeles, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Active, not recruiting Phase 2 Interventional

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

NCT07228390
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

NCT02808975
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Placebo, Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Beverly Hills, California • Encino, California • Irvine, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 25, 2026, 5:09 AM EDT
Withdrawn No phase listed Observational

A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa

NCT05255575
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ertapenem
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 25, 2026, 5:09 AM EDT
Recruiting Early Phase 1 Interventional

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

NCT06058520
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Fecal Microbiota - lyophilized, Placebo drug
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Completed Early Phase 1 Interventional

Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

NCT03099980
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Sep 25, 2026, 5:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Treatment of Hidradenitis Suppurativa Using Etanercept

NCT00949546
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
etanercept
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 25, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

Wound Dressings for Hidradenitis Suppurativa

NCT04194541
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Cutimed Sorbact Hydroactive B wound dressing, Cutimed Siltect wound dressing, Sorbion Sana multi-star wound dressing
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 25, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07225569
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
SAR445399, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Scottsdale, Arizona • North Hollywood, California • Boynton Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

NCT04762277
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab - solution for infusion, Placebo matching spesolimab - solution for infusion, Spesolimab- solution for injection, Placebo matching to spesolimab- solution for injection
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 25, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

NCT03852472
View directory record Official record
Conditions
Hidradenitis Suppurativa, Acne Inversa
Interventions
Avacopan, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
91
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 25, 2026, 5:09 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

NCT07316192
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Pelashield Painguard
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 5:09 AM EDT
Not listed Phase 4 Interventional

A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions

NCT05477225
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
NovoSorb® BTM, Human Cadaveric Allograft
Device
Lead sponsor
Joseph M. Still Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 25, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT05620823
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Povorcitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Phoenix, Arizona • Arkansas City, Arkansas • Fort Smith, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 25, 2026, 5:09 AM EDT